Contineum Therapeutics, Inc. (NASDAQ:CTNM) shares are trading lower on Tuesday as Phase 2 results from a key study disappoint.
The pullback lines up with a risk-off tone in futures, but the company-specific clinical update appears to be the main driver.
CTNM Stock Drops After Phase 2 MOONLIGHT-1 Results
The company said its Phase 2 MOONLIGHT-1 trial did not meet its primary efficacy endpoint for JNJ-5120 / PIPE-307 in major depressive disorder.
JNJ-5120/PIPE-307 is being developed by Johnson & Johnson (NYSE:JNJ) under a global license and development agreement.
Johnson & Johnson continues to evaluate the trial data, including data related to prespecified exploratory endpoints, and assess the totality and clinical relevance of the findings to inform next steps for JNJ-5120/PIPE-307.
Trend Setup Versus News-Driven Volatility
The bigger-picture backdrop is still constructive on paper—there’s a bullish 20-day-over-50-day alignment and a golden cross (50-day SMA over 200-day SMA) that dates back to September 2025—but the premarket drop risks turning that into a "trend vs. news" tug-of-war. With the 52-week range spanning $8.60 to $17.79 and a 52-week high set in September, traders will be watching whether this dip becomes another higher low or the start of a deeper reset.
- Key Resistance: $15.34 — near the 50-day SMA, a common level where rebounds can run into selling
- Key Support: $13.60 — aligned with the 200-day SMA, a key long-term trend line
How CTNM Ranks On Benzinga Edge Momentum
Below is the Benzinga Edge scorecard for Contineum Therapeutics, highlighting its strengths and weaknesses compared to the broader market:
- Momentum: Bullish (Score: 77.61) — The stock has been showing stronger-than-average momentum on a multi-week basis, even with the current premarket dip.
The Verdict: Contineum Therapeutics’ Benzinga Edge signal reveals a momentum-driven profile, with Momentum as the only scored pillar currently available.
With today’s news-driven gap lower, traders will likely treat that momentum score as "under review" until the stock proves it can reclaim key moving averages on follow-through volume.
CTNM Price Action: Contineum Therapeutics shares were down 9.58% at $13.40 at the time of publication on Tuesday, according to Benzinga Pro data.
Photo: Shutterstock